Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isomyosamine for Sarcopenia Post-Hip Fracture
NCT06942182Phase 2Not yet recruiting
- Sponsor
- TNF Pharmaceuticals, Inc.
- Start
- May 2025
- Primary completion
- Mar 2026
- Modality
- Classical Binding Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Sarcopenia and frailty syndrome comparing Isomyosamine Arm with Placebo Arm (2 arms). Primary endpoint: Change in Short Physical Performance Battery at 90 days. Planned start May 2025; status: not yet recruiting.
02
Drugs
isomyosamine
03
Conditions
Sarcopeniafrailty syndrome
Beyond the preview
Go deeper on NCT06942182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942182.